Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,468 shares of the company’s stock after buying an additional 2,047 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $2,930,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of NBIX. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at about $509,000. Cetera Investment Advisers increased its holdings in shares of Neurocrine Biosciences by 7.9% during the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock worth $979,000 after buying an additional 519 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at approximately $510,000. Handelsbanken Fonder AB lifted its holdings in Neurocrine Biosciences by 20.7% in the third quarter. Handelsbanken Fonder AB now owns 26,867 shares of the company’s stock valued at $3,096,000 after acquiring an additional 4,600 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Neurocrine Biosciences by 11.9% in the third quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock worth $200,000 after acquiring an additional 185 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. UBS Group boosted their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average price target of $166.10.

Insider Buying and Selling

In related news, Director Kevin Charles Gorman sold 146,105 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the transaction, the director now directly owns 514,596 shares of the company’s stock, valued at $76,911,518.16. This trade represents a 22.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 214,799 shares of company stock worth $31,513,583. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Down 1.0 %

Shares of Neurocrine Biosciences stock opened at $151.82 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The company has a 50 day moving average of $136.97 and a 200 day moving average of $131.62. The company has a market capitalization of $15.37 billion, a P/E ratio of 40.70 and a beta of 0.33.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.